Back
Compare AU
Compare LHGG vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Lakehouse Global Growth Fund Active ETF (LHGG) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
LHGG | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 81 | 73 |
Median incremental investment | $1,681.70 | $736.96 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,614.36 | $2,083.88 |
Average age group | > 35 | > 35 |
Key Summary
LHGG | DRUG | |
|---|---|---|
Strategy | LHGG.AX was created on 2017-12-01 by Global X. The fund's investment portfolio concentrates primarily on total market equity. The Funds investment objective is to provide long-term capital growth and to outperform the MSCI All Country World Index Net Total Returns in AUD over rolling five-year periods (after fees and expenses but before taxes). | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | MercadoLibre Inc (12.62 %) ServiceNow Inc (10.16 %) Workiva Inc Class A (8.82 %) | BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) |
Top 3 industries | Consumer Discretionary (29.58 %) Information Technology (20.26 %) Communication Services (17.49 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | United States (54.80 %) Canada (12.71 %) Brazil (12.45 %) | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) |
Management fee | 0 % | 0.57 % |
Key Summary
LHGG | DRUG | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | MSCI All Country World Index - USD - Benchmark TR Net | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0 % | 0.57 % |
Price | $1.845 | $8.83 |
Size | N/A | $174.867 million |
10Y return | N/A | 81.31 % |
Annual distribution yield (5Y) | 7.48 % | 1.82 % |
Market | ASX | ASX |
First listed date | 06/04/2025 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
LHGG | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 81 | 73 |
Median incremental investment | $1,681.70 | $736.96 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,614.36 | $2,083.88 |
Average age group | > 35 | > 35 |
Pros and Cons
LHGG | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
LHGG | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |